A Dark Vector Cognition product

Item 16. FORM 10-K SUMMARY

3K characters. Original on sec.gov · Markdown

Item 16. FORM 10-K SUMMARY

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

GILEAD SCIENCES, INC.
By:/S/ GREGG H. ALTON
Gregg H. Alton Interim Chief Executive Officer and Chief Patient Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Gregg H. Alton and Brett A. Pletcher, and each of them, as his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments to this Report, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or any of them or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

SignatureTitleDate
/S/ GREGG H. ALTONInterim Chief Executive Officer and Chief Patient OfficerFebruary 25, 2019
Gregg H. Alton(Principal Executive Officer)
/S/ ROBIN L. WASHINGTONExecutive Vice President and Chief Financial OfficerFebruary 25, 2019
Robin L. Washington(Principal Financial and Accounting Officer)
/S/ JOHN C. MARTINChairman of the Board of DirectorsFebruary 25, 2019
John C. Martin, Ph.D.
/S/ JACQUELINE K. BARTONDirectorFebruary 25, 2019
Jacqueline K. Barton, Ph.D.
/S/ JOHN F. COGANDirectorFebruary 25, 2019
John F. Cogan, Ph.D.
/S/ KELLY A. KRAMERDirectorFebruary 25, 2019
Kelly A. Kramer
/S/ KEVIN E. LOFTONDirectorFebruary 25, 2019
Kevin E. Lofton
/S/ NICHOLAS G. MOOREDirectorFebruary 25, 2019
Harish Manwani
/S/ RICHARD J. WHITLEYDirectorFebruary 25, 2019
Richard J. Whitley, M.D.
/S/ GAYLE E. WILSONDirectorFebruary 25, 2019
Gayle E. Wilson
/S/ PER WOLD-OLSENDirectorFebruary 25, 2019
Per Wold-Olsen

Previous: Item 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES